# Clinical trials recruiting in Tennessee: 2,068 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,068 trials recruiting or not yet recruiting with a site in Tennessee, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Tennessee: 2,068 rows for $100.68, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 39 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/tennessee

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,068
- Recruiting or not yet: 2,068
- Read on: November 19, 2026

## Trials

The 25 newest of 2,068, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07943741 | Ketamine for Treatment of Alzheimers Disease Related Depression | Vanderbilt University Medical Center | Phase 2 | Not yet recruiting | Late Life Depression (LLD), MCI, MCI-AD, Early Stage Alzheimer&#39;s Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943741) |
| November 17, 2026 | NCT07941531 | T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies. | St. Jude Children's Research Hospital | Phase 1 | Not yet recruiting | Lymphoma, AML, T-ALL, Hematologic Malignancy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941531) |
| November 16, 2026 | NCT07939529 | People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | HIV Viremia | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939529) |
| November 12, 2026 | NCT07932665 | Evaluation of the TAP-Preschool (TAP-P) for Tele-assessment of Autism in Preschool-aged Children | Vanderbilt University Medical Center | Not applicable | Recruiting | Autism | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932665) |
| November 12, 2026 | NCT07931703 | Safety, Tolerability and Efficacy of RGH-202 in Social Anxiety Disorder (STAGE) | Gedeon Richter Plc. | Phase 2 | Not yet recruiting | Social Anxiety Disorder | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931703) |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 12, 2026 | NCT07931547 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931547) |
| November 12, 2026 | NCT07930429 | The MInimizing RIsk of CLotting Events Trial | National Heart, Lung, and Blood Institute (NHLBI) | Not applicable | Not yet recruiting | Venous Thromboembolism (VTE) | 65,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930429) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 4, 2026 | NCT07917208 | Early Feasibility Study of the Capstan Medical TMVR System | Capstan Medical | Not applicable | Recruiting | Mitral Regurgitation (MR) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917208) |
| November 4, 2026 | NCT07916389 | Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma | St. Jude Children's Research Hospital | Phase 2 | Not yet recruiting | Infant-Type Hemispheric Glioma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916389) |
| November 2, 2026 | NCT07908316 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After... | Amgen | Phase 1 | Recruiting | Obesity, Overweight | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908316) |
| October 30, 2026 | NCT07907991 | The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907991) |
| October 30, 2026 | NCT07907783 | Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia | Pelage Pharmaceuticals, Inc. | Phase 2 | Recruiting | Androgenetic Alopecia | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907783) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 28, 2026 | NCT07901647 | Evaporative Dry Eye | Southern College of Optometry | Phase 4 | Not yet recruiting | Dry Eye, Evaporative Dry Eye, Evaporative Dry Eye Disease | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901647) |
| October 27, 2026 | NCT07897370 | Cardiac Arrest - Ultrasound Detection of Occult Perfusion | University of Massachusetts, Worcester | Observational | Recruiting | Cardiac Arrest, Out-Of-Hospital, Hypotension | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897370) |
| October 22, 2026 | NCT07890376 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | Eli Lilly and Company | Phase 2 | Not yet recruiting | Obesity, Overweight | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890376) |
| October 21, 2026 | NCT07885085 | Postsurgical Pain and Opioid Use in Older Adults: Effects of Mild Cognitive Impairment | Sponsor not shown (see the record) | Observational | Not yet recruiting | Mild Cognitive Impairment (MCI), Opioid Use, Cognitive Dysfunction, Postoperative Pain | 552 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885085) |
| October 20, 2026 | NCT07884474 | Feasibility and Acceptability of Remote Saliva Collection | St. Jude Children's Research Hospital | Observational | Recruiting | Survivors of Childhood Cancer, Acute Lymphoblastic Leukemia, Childhood | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884474) |
| October 20, 2026 | NCT07882927 | Stigma Healing Inventory Evaluation | St. Jude Children's Research Hospital | Not applicable | Recruiting | Stigma | 2,980 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882927) |
| October 19, 2026 | NCT07881809 | A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | HIV (Human Immunodeficiency Virus) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881809) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 19, 2026 | NCT07880743 | Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Pain, Postoperative | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880743) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Vanderbilt University Medical Center | Nashville | 360 |
| SCRI Oncology Partners | Nashville | 136 |
| St. Jude Children's Research Hospital | Memphis | 130 |
| Vanderbilt University/Ingram Cancer Center | Nashville | 93 |
| Tennessee Oncology | Nashville | 64 |
| Sarah Cannon Research Institute | Nashville | 63 |
| Baptist Memorial Hospital and Cancer Center-Memphis | Memphis | 51 |
| Vanderbilt University | Nashville | 48 |
| Baptist Memorial Hospital and Cancer Center-Collierville | Collierville | 42 |
| Vanderbilt-Ingram Cancer Center | Nashville | 38 |
| University of Tennessee Medical Center | Knoxville | 32 |
| Saint Jude Children's Research Hospital | Memphis | 28 |
| East Tennessee Childrens Hospital | Knoxville | 27 |
| The Children's Hospital at TriStar Centennial | Nashville | 25 |
| University of Tennessee - Knoxville | Knoxville | 22 |
| Le Bonheur Children's Hospital | Memphis | 21 |
| Vanderbilt Breast Center at One Hundred Oaks | Nashville | 18 |
| West Tennessee Research Institute | Jackson | 13 |
| Tennessee Oncology, PLLC | Nashville | 13 |
| University of Tennessee Health Science Center | Memphis | 12 |
| Tennessee Cancer Specialists | Knoxville | 12 |
| Baptist Cancer Center | Memphis | 12 |
| TriStar Centennial Medical Center | Nashville | 12 |
| Monroe Carell Jr. Children's Hospital at Vanderbilt | Nashville | 11 |
| University of Tennessee | Knoxville | 11 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 14 |
| Phase 1 | 255 |
| Phase 1/2 | 199 |
| Phase 2 | 358 |
| Phase 2/3 | 45 |
| Phase 3 | 522 |
| Phase 4 | 69 |
| Not applicable | 309 |
| Observational | 297 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 129 |
| Neoplasms | 100 |
| Breast Neoplasms | 96 |
| Neoplasm Metastasis | 80 |
| Colorectal Neoplasms | 77 |
| Lung Neoplasms | 63 |
| Ovarian Neoplasms | 53 |
| Squamous Cell Carcinoma of Head and Neck | 50 |
| Prostatic Neoplasms | 50 |
| Pancreatic Neoplasms | 48 |
| Obesity | 46 |
| Endometrial Neoplasms | 45 |
| Melanoma | 44 |
| Recurrence | 40 |
| Multiple Myeloma | 37 |
| Urinary Bladder Neoplasms | 37 |
| Stomach Neoplasms | 36 |
| Leukemia, Myeloid, Acute | 34 |
| Heart Failure | 33 |
| Triple Negative Breast Neoplasms | 32 |
| Carcinoma, Renal Cell | 29 |
| Lymphoma, Non-Hodgkin | 28 |
| Carcinoma, Transitional Cell | 28 |
| Diabetes Mellitus, Type 2 | 27 |
| Head and Neck Neoplasms | 27 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Vanderbilt University Medical Center | 119 |
| St. Jude Children's Research Hospital | 99 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 60 |
| National Cancer Institute (NCI) | 49 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 41 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 35 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 34 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 31 |
| Vanderbilt-Ingram Cancer Center | 31 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 31 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 26 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 26 |
| Children's Oncology Group | 26 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 23 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 22 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 22 |
| SWOG Cancer Research Network | 20 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 18 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 16 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 15 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 15 |
| VA Office of Research and Development | 15 |
| NRG Oncology | 14 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 13 |
| Vanderbilt University | 13 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Tennessee

- [Wineries in Tennessee, United States](https://specstream.ai/data/businesses/wineries/tennessee-united-states)
- [Packing supply stores in Tennessee, United States](https://specstream.ai/data/businesses/packing-supply-stores/tennessee-united-states)
- [Farming services in Tennessee, United States](https://specstream.ai/data/businesses/farming-services/tennessee-united-states)
- [Appraisers in Tennessee, United States](https://specstream.ai/data/businesses/appraisers/tennessee-united-states)
- [Plastics companies in Tennessee, United States](https://specstream.ai/data/businesses/plastics-companies/tennessee-united-states)
- [Furniture manufacturers in Tennessee, United States](https://specstream.ai/data/businesses/furniture-manufacturers/tennessee-united-states)
